Clovis Agrees To Reforms, $2.3M Atty Fee In Drug Trial Suit
Cancer drug researcher Clovis Oncology Inc. has agreed to pay a $2.3 million attorney fee and adopt corporate governance reforms to settle a 5-year-old derivative suit originally alleging insider trading and...To view the full article, register now.
Already a subscriber? Click here to view full article